Abstract:Background: Esculentoside A (EsA) has had a remarkable curative effect on a variety of experimental acute and chronic inflammatory and autoimmune diseases. However, the role of EsA in the pathological process of ulcerative colitis (UC) is still unknown.Methods: Rat colonic smooth muscle cells (SMCs) were identified by immunofluorescence. The effect of EsA and/or lipopolysaccharide (LPS) on the viability, proliferation, and apoptosis of SMCs was explored via 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT), 5-ethynyl-2'-deoxyuridine (EdU) staining, flow cytometry, and TdT-mediated dUTP nick end labeling (TUNEL) staining, respectively. The changes of apoptosis-related proteins were performed via western blotting. The expression and nuclear translocation of NF-κB were detected via western blotting, immunohistochemistry (IHC), and immunofluorescence staining, respectively. Enzyme-linked immunosorbent assay (ELISA) was used to detect the expression of IL-6 and TNF-α.Results: The EsA treatment greatly up-regulated the viability of LPS-suppressed SMCs. The LPS-induced cell apoptosis was significantly reversed by EsA treatment, which was achieved via down-regulating Bax and cleaved caspase-3 expression and up-regulating Bcl-2 expression. In addition, LPS-induced IL-6, TNF-α expression and NF-κB activation were also largely decreased when treated with EsA. <i>In vivo</i>, the TNBS-induced colon injury including crypt destruction and crypt deformation, disorder, epithelial cell remains or complete destruction, and inflammatory cell infiltration was recovered by EsA treatment. The secretion of IL-6 and TNF-α in the serum of the model group was also down-regulated by EsA treatment. The expression of Bax, cleaved caspase-3, and Bcl-2 showed similar trends as those observed in the <i>in vitro</i> experiments.Conclusions: Our data provides supportive evidence that EsA can relieve the symptoms of UC and be used as a drug candidate for the treatment of UC.

Esculentoside A Specifically Binds to Ribosomal Protein S3a and Impairs LPS-induced Signaling in Macrophages

Esculentoside A exerts anti-inflammatory activity in microglial cells

Salvianic Acid A Inhibits Induction of Inflammatory Mediators by Blocking Nuclear Factor-κB Activation in Macrophages

Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice.

Effects of Esculentoside A on Production of Interleukin-1, 2, and Prostaglandin E2

Esculentoside A Inhibits Tumor Necrosis Factor, Interleukin-1, and Interleukin-6 Production Induced by Lipopolysaccharide in Mice.

Effects of Esculentoside A on Autoimmune Syndrome Induced by Campylobacterjejuni in Mice and Its Modulation on T-lymphocyte Proliferation and Apoptosis.

ESeroS-GS modulates lipopolysaccharide-induced macrophage activation by impairing the assembly of TLR-4 complexes in lipid rafts.

Saikosaponin a Inhibits LPS-induced Inflammatory Response by Inducing Liver X Receptor Alpha Activation in Primary Mouse Macrophages.

Esculentoside A could attenuate apoptosis and inflammation in TNBS-induced ulcerative colitis via inhibiting the nuclear translocation of NF-κB

Effects of Esculentoside A on TNF-α and Sil-2R Levels in Peripheral Blood Mononuclear Cells from Psoriatic Patients

Saponin Esculeoside A and Aglycon Esculeogenin A from Ripe Tomatoes Inhibit Dendritic Cell Function by Attenuation of Toll-like Receptor 4 Signaling

The Polysaccharide from the Roots of Actinidia Eriantha Activates RAW264.7 Macrophages Via Regulating Microrna Expression.

Esculentoside A Attenuates Allergic Airway Inflammation Via Activation of the Nrf-2 Pathway

In silico analysis and experimental validation of molecular mechanisms of salvianolic acid A-inhibited LPS-stimulated inflammation, in RAW264.7 macrophages.

Saikosaponin A mediates the inflammatory response by inhibiting the MAPK and NF-κB pathways in LPS-stimulated RAW 264.7 cells.

The Effect Of Esculentoside A On Lupus Nephritis-Prone Bxsb Mice

Eburicoic acid from Laetiporus sulphureus (Bull.:Fr.) Murrill attenuates inflammatory responses through inhibiting LPS-induced activation of PI3K/Akt/mTOR/NF-κB pathways in RAW264.7 cells

Esculentoside A Protects Against Osteoarthritis by Ameliorating Inflammation and Repressing Osteoclastogenesis.

Esculentoside A Suppresses Aβ1–42-induced Neuroinflammation by Down-Regulating MAPKs Pathwaysin Vivo

As-703026 Inhibits Lps-Induced Tnfa Production Through Mek/Erk Dependent And Independent Mechanisms